If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® ▼ (ixekizumab): What is the dosing regimen in axial spondyloarthritis?
160 mg at week 0, then 80 mg every 4 weeks.
Dosage Regimen in Radiographic and Non-radiographic Axial
recommended dose is 160 mg (two 80 mg injections) by
subcutaneous injection at Week 0, followed by 80 mg every
should be given to discontinuing treatment in patients who have shown
no response after 16 to 20 weeks of treatment.1
patients with initially partial response may subsequently improve
with continued treatment beyond 20 weeks.1
dose adjustment is required in elderly patients (≥ 65years).1
is limited information in subjects aged ≥ 75 years.1
has not been studied in patients with renal or hepatic impairment. No
dose recommendations can be made.1
is for subcutaneous injection. Injection sites may be alternated. If
possible, areas of the skin that show psoriasis should be avoided as
injection sites. The solution/the syringe must not be shaken.1
proper training in subcutaneous injection technique, patients may
self-inject ixekizumab if a healthcare professional determines that
it is appropriate. However, the physician should ensure appropriate
follow-up of patients. Comprehensive instructions for administration
are given in the package leaflet.1
Taltz [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:June 17, 2020
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org